Insulet Reports EVOLUTION 2 Study Results for FCL Automated Insulin Delivery System in Type 2 Diabetes

Why It Matters

The study shows a fully closed‑loop system can safely boost glycemic control in type 2 diabetes without bolus dosing, opening a new market segment for automated insulin therapy. Successful pivotal data could fast‑track regulatory clearance and shift prescribing practices toward technology‑driven diabetes management.

Key Takeaways

• FCL system raised TIR to 68% in T2D patients
• No bolus insulin required during study
• Time below range stayed under 0.2% with no severe events
• Over 90% participants entered extension phase
• Pivotal EVOLVE trial slated for 2026, launch 2028

Pulse Analysis

Automated insulin delivery (AID) has traditionally focused on type 1 diabetes, where tight glucose control is essential. Extending this technology to type 2 diabetes addresses a far larger patient pool—over 100 million adults in the United States alone—who often rely on multiple daily injections and oral agents. By eliminating the need for manual bolus calculations, a fully closed‑loop system simplifies therapy, reduces user error, and aligns with the broader trend toward digital health integration.

The EVOLUTION 2C feasibility results are noteworthy for both efficacy and safety. An average TIR of 68% represents a substantial 24% gain over conventional injection regimens, while the median time‑below‑range of just 0.14% demonstrates that the algorithm can avoid hypoglycemia without sacrificing glucose control. Importantly, the study reported zero severe hypoglycemia or diabetic ketoacidosis events, underscoring the system’s reliability in a real‑world cohort spanning ages 16 to 70. Such outcomes provide clinicians with confidence that closed‑loop automation can be a viable adjunct or alternative to existing treatment pathways.

Looking ahead, Insulet’s roadmap—moving from feasibility to the EVOLVE pivotal trial in 2026, a 510(k) submission in 2027, and a projected 2028 market entry—signals a strategic push to capture the type 2 diabetes segment. Regulatory approval would not only validate the technology but also likely stimulate competition, driving innovation and price dynamics across the insulin delivery market. For investors and industry watchers, the timeline suggests a near‑term inflection point where AID could become a standard of care for a broader diabetic population, reshaping reimbursement models and patient outcomes.